Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.
Deciphering which businesses can sustain their high growth rates is a challenge for even the most seasoned professionals, which is why we started StockStory. Keeping that in mind, here are two growth stocks with significant upside potential and one climbing an uphill battle.
One Growth Stock to Sell:
American Express Global Business Travel (GBTG)
One-Year Revenue Growth: +20.7%
Originally spun off from American Express in 2014 but maintaining the Amex GBT brand, Global Business Travel Group (NYSE: GBTG) provides end-to-end business travel and expense management solutions, connecting corporate clients with travel suppliers and offering specialized software services.
Why Are We Cautious About GBTG?
- Annual revenue growth of 12.5% over the last two years was below our standards for the software sector
- Gross margin of 59% reflects its high servicing costs
- Efficiency has decreased over the last year as its operating margin fell by 3.7 percentage points
At $9.43 per share, American Express Global Business Travel trades at 1.5x forward price-to-sales. Read our free research report to see why you should think twice about including GBTG in your portfolio.
Two Growth Stocks to Watch:
Globus Medical (GMED)
One-Year Revenue Growth: +23.5%
With operations spanning 64 countries and a portfolio of over 10 new products launched in 2023 alone, Globus Medical (NYSE: GMED) develops and sells implantable devices, surgical instruments, and technology solutions for spine, orthopedic, and neurosurgical procedures.
Why Are We Fans of GMED?
- Market share has increased this cycle as its 30.3% annual revenue growth over the last five years was exceptional
- Steady constant currency growth over the past two years shows the company can pursue its global ambitions, even in uncertain economic times
- Earnings per share have massively outperformed its peers over the last five years, increasing by 22.2% annually
Globus Medical is trading at $85.50 per share, or 17.7x forward P/E. Is now the right time to buy? See for yourself in our full research report, it’s free.
Tradeweb Markets (TW)
One-Year Revenue Growth: +18.3%
Founded in 1996 as one of the pioneers in electronic bond trading, Tradeweb Markets (NASDAQ: TW) builds and operates electronic marketplaces that connect financial institutions for trading across rates, credit, equities, and money markets.
Why Is TW a Top Pick?
- Annual revenue growth of 23.4% over the past two years was outstanding, reflecting market share gains this cycle
- Earnings growth has trumped its peers over the last two years as its EPS has compounded at 23.5% annually
Tradeweb Markets’s stock price of $102.10 implies a valuation ratio of 25.9x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
